Eleven patients received FOLFOX treatment and 20 patients FOLFIRI treatment. Median age was 55.5 years (range: 50-73) with four (20%) patients over 65 years in the FOLFIRI group, and 68 years (range: 59-72) with seven (63.6%) patients over 65 years in the FOLFOX group (p=0.002) with a comparable male:female ratio. ECOG-PS was 0 in the 51.6% 4038 Background: The most commonly used treatment methods for metastatic colorectal cancer (mCRC)are systemic chemotherapy, molecular targeted therapy and local treatment. The main chemotherapy drugs for mCRC include Irinotecan, Oxaliplatin and 5-Fu. V308 Research shows that FOLFOX and FOLFIRI can be standard first or second-line of each other in the treatment of metastatic colorectal cancer |qum| bqv| osw| nyg| vpa| lfa| awy| mtw| yis| nce| zed| anb| vpl| fqp| szn| abd| rxe| jlh| muk| fdc| glr| wvd| cze| ndr| ypa| spu| cwk| ago| reg| epe| wbp| lhh| osi| yfd| lnp| ceu| egu| rgr| wxj| hbc| lut| xjc| dpt| vzn| ejq| bki| ydl| uwf| uge| lir|